by Eric Christianson | Aug 25, 2021 | Medication and Disease State Clinical Pearls For Pharmacists
Gabapentin and pregabalin are anticonvulsants utilized in a wide array of conditions. These drugs share a similar chemical structure and share many of the same uses, so let’s take a look at gabapentin versus pregabalin? Mechanism of action: The precise mechanism...
by Eric Christianson | Aug 22, 2021 | Medication and Disease State Clinical Pearls For Pharmacists
Anticholinergic medications are well known for their often dose-limiting adverse effects, so do any of the medications typically used in the treatment of lower urinary tract symptoms (LUTS) associated with BPH stand above the others with a more favorable adverse...
by Eric Christianson | Aug 18, 2021 | Cardiovascular Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
As one of the few significant new treatment options approved for reducing the risk of cardiovascular events since statins were approved about 30 years ago, when should icosapent ethyl (Vascepa) actually be used? Icosapent ethyl, sold as Vascepa by Amarin, is a...
by Eric Christianson | Aug 15, 2021 | Clinical Guideline Updates For Pharmacists
Treatment for patients hospitalized with COVID-19 is continuously evolving. Some medications have proven beneficial over the past year, while others have fallen out of favor. Here we review the most recent guidelines as of August 2021. In short, it is...
by Eric Christianson | Aug 11, 2021 | Clinical Guideline Updates For Pharmacists
Community-acquired pneumonia (CAP) is defined as pneumonia acquired outside of hospitals, (less than 48 hours from hospital admission). Patients will typically present with symptoms including fever, chills, chest pain, cough, sputum production, and dyspnea. Objective...
